Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

Inclusion Criteria:

• Pinguecula with a vascularity grade ≥ 3 on a 5-point (0-4) scale.
• Ocular bothersome questionnaire score ≥ 2 on a 5-point (0-4) scale.
• ≥ 18 years of age.
• Able to provide written informed consent and comply with study assessments for thefull duration of the study.

Exclusion Criteria:

• Uncontrolled systemic disease, in the opinion of the investigator.
• Active ocular disease other than pinguecula that may confound the study data,including but not limited to severe dry eye disease, pterygium, uncontrolledblepharitis, anterior membrane dystrophy, Salzmann's, glaucoma, or active ocularinfection.
• History of ocular herpes disease, iritis/uveitis, in either eye.
• Any ocular surgical procedure within the last 3 months or anticipated ocular surgeryduring the study, in either eye.
• Anticipated wearing of contact lenses during any portion of the study. Patients, whowear soft contact lenses should discontinue wearing them at least 7 days prior to Day 1 visit. Patients wearing rigid gas permeable or hard contact lenses shoulddiscontinue wearing them at least 3 weeks prior to Day 1 visit.
• Female patients who are pregnant, nursing, or planning a pregnancy during the study.
• Current enrollment in an investigational drug or device study or participation in sucha study within 30 days prior to entry into this study.
• History of myocardial infarction or stroke.
• Any condition or situation which, in the investigator's opinion, may put the patientat significant risk, may confound the study results, or may interfere significantlywith the patient's participation in the study.
• Known allergy or sensitivity to the study medication(s) or its components.
• Current or anticipated use of topical ophthalmic medications in the study eye.Patients must have discontinued use of ophthalmic medications in the study eye for atleast 2 weeks (4 weeks for Restasis® or Xiidra®) prior to Day 1 visit. Artificialtears are allowed in the study eye until 7 days prior to Visit 1 and should not beused during the treatment phase of the study.